HAYA Therapeutics has initiated a Phase 1 trial of HTX-001, an antisense oligonucleotide targeting WISPER long non-coding RNA to reverse cardiac fibrosis and restore myocardial function. The approach addresses a fundamental mechanism of age-related heart failure by reprogramming fibrotic cells back to a functional state, targeting a condition affecting 30-60% of hypertrophic cardiomyopathy cases.
Key Points
- HTX-001 targets WISPER RNA to reverse pathological cardiac fibrosis
- Preclinical data show improvements in heart function and reduced fibrosis
- Phase 1 trial enrolling healthy volunteers and nHCM patients
Longevity Analysis
Cardiac fibrosis is a central feature of age-related heart disease and a primary mechanism by which the heart loses its capacity to pump effectively. Rather than masking symptoms, HTX-001 addresses the cellular state change that drives fibrosis — converting myofibroblasts away from their pathological phenotype. This represents a shift from managing hemodynamic dysfunction to eliminating the underlying cellular reprogramming that accumulates with age. If successful, this approach could restore functional capacity in hearts already compromised by years of fibrotic remodeling, directly extending both lifespan and healthspan by preserving one of the body's most critical functions.
Original published by LT Wire.